Evolutionary biology of high-risk multiple myeloma
Nature Reviews Cancer 17, 543 (2017).
doi:10.1038/nrc.2017.63
Authors: Charlotte Pawlyn & Gareth J. Morgan
The outcomes for the majority of patients with myeloma have improved over recent decades, driven by treatment advances. However, there is a subset of patients considered to have high-risk disease who have not benefited. Understanding how high-risk disease evolves from more therapeutically tractable stages is
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Charlotte Pawlyn Gareth J. Morgan Tags: Review Source Type: research